1. Home
  2. NGNE vs MOV Comparison

NGNE vs MOV Comparison

Compare NGNE & MOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

N/A

Current Price

$25.43

Market Cap

744.9M

Sector

Health Care

ML Signal

N/A

Logo Movado Group Inc.

MOV

Movado Group Inc.

N/A

Current Price

$31.35

Market Cap

690.8M

ML Signal

N/A

Company Overview

Basic Information
Metric
NGNE
MOV
Founded
2003
1961
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Consumer Specialties
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
690.8M
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
NGNE
MOV
Price
$25.43
$31.35
Analyst Decision
Strong Buy
Buy
Analyst Count
10
2
Target Price
★ $77.88
$47.50
AVG Volume (30 Days)
★ 342.8K
137.4K
Earning Date
11-20-2026
11-24-2026
Dividend Yield
N/A
★ 5.13%
EPS Growth
0.93
★ 44.44
EPS
N/A
★ 0.84
Revenue
N/A
★ $338,600,000.00
Revenue This Year
N/A
$5.41
Revenue Next Year
N/A
$4.47
P/E Ratio
★ N/A
$39.06
Revenue Growth
N/A
★ 25.73
52 Week Low
$15.93
$17.83
52 Week High
$43.66
$40.50

Technical Indicators

Market Signals
Indicator
NGNE
MOV
Relative Strength Index (RSI) 47.84 42.89
Support Level $24.88 $30.83
Resistance Level $28.47 $33.98
Average True Range (ATR) 2.50 0.81
MACD 0.38 0.04
Stochastic Oscillator 35.88 24.68

Price Performance

Historical Comparison
NGNE
MOV

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About MOV Movado Group Inc.

Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.

Share on Social Networks: